BACKGROUND: Emerging evidence has suggested that the capability to sustain tumor formation, growth, and chemotherapy resistance in ovarian as well as other human malignancies exclusively resides in a small proportion of tumor cells termed cancer stem cells. During the characterization of CD44(+) ovarian cancer stem cells, we found a high expression of the genes encoding for claudin-4. Because this tight junction protein is the natural high-affinity receptor for Clostridium perfringens enterotoxin (CPE), we have extensively investigated the sensitivity of ovarian cancer stem cells to CPE treatment in vitro and in vivo. METHODS: Real-time polymerase chain reaction and flow cytometry were used to evaluate claudin-3/-4 expression in ovarian cancer stem cells. Small interfering RNA knockdown experiments and MTS assays were used to evaluate CPE-induced cytotoxicity against ovarian cancer stem cell lines in vitro. C.B-17/SCID mice harboring ovarian cancer stem cell xenografts were used to evaluate CPE therapeutic activity in vivo. RESULTS: CD44(+) ovarian cancer stem cells expressed claudin-4 gene at significantly higher levels than matched autologous CD44(-) ovarian cancer cells, and regardless of their higher resistance to chemotherapeutic agents died within 1 hour after exposure to 1.0 μg/mL of CPE in vitro. Conversely, small-interfering RNA-mediated knockdown of claudin-3/-4 expression in CD44(+) cancer stem cells significantly protected cancer stem cells from CPE-induced cytotoxicity. Importantly, multiple intraperitoneal administrations of sublethal doses of CPE in mice harboring xenografts of chemotherapy-resistant CD44(+) ovarian cancer stem cells had a significant inhibitory effect on tumor progression leading to the cure and/or long-term survival of all treated animals (ie, 100% reduction in tumor burden in 50% of treated mice; P < .0001). CONCLUSIONS: CPE may represent an unconventional, potentially highly effective strategy to eradicate chemotherapy-resistant cancer stem cells.
BACKGROUND: Emerging evidence has suggested that the capability to sustain tumor formation, growth, and chemotherapy resistance in ovarian as well as other humanmalignancies exclusively resides in a small proportion of tumor cells termed cancer stem cells. During the characterization of CD44(+) ovarian cancer stem cells, we found a high expression of the genes encoding for claudin-4. Because this tight junction protein is the natural high-affinity receptor for Clostridium perfringens enterotoxin (CPE), we have extensively investigated the sensitivity of ovarian cancer stem cells to CPE treatment in vitro and in vivo. METHODS: Real-time polymerase chain reaction and flow cytometry were used to evaluate claudin-3/-4 expression in ovarian cancer stem cells. Small interfering RNA knockdown experiments and MTS assays were used to evaluate CPE-induced cytotoxicity against ovarian cancer stem cell lines in vitro. C.B-17/SCIDmice harboring ovarian cancer stem cell xenografts were used to evaluate CPE therapeutic activity in vivo. RESULTS:CD44(+) ovarian cancer stem cells expressed claudin-4 gene at significantly higher levels than matched autologous CD44(-) ovarian cancer cells, and regardless of their higher resistance to chemotherapeutic agents died within 1 hour after exposure to 1.0 μg/mL of CPE in vitro. Conversely, small-interfering RNA-mediated knockdown of claudin-3/-4 expression in CD44(+) cancer stem cells significantly protected cancer stem cells from CPE-induced cytotoxicity. Importantly, multiple intraperitoneal administrations of sublethal doses of CPE in mice harboring xenografts of chemotherapy-resistant CD44(+) ovarian cancer stem cells had a significant inhibitory effect on tumor progression leading to the cure and/or long-term survival of all treated animals (ie, 100% reduction in tumor burden in 50% of treated mice; P < .0001). CONCLUSIONS:CPE may represent an unconventional, potentially highly effective strategy to eradicate chemotherapy-resistant cancer stem cells.
Authors: David S Alberts; Maurie Markman; Deborah Armstrong; Mace L Rothenberg; Franco Muggia; Stephen B Howell Journal: J Clin Oncol Date: 2002-10-01 Impact factor: 44.544
Authors: P Michl; M Buchholz; M Rolke; S Kunsch; M Löhr; B McClane; S Tsukita; G Leder; G Adler; T M Gress Journal: Gastroenterology Date: 2001-09 Impact factor: 22.682
Authors: Charles N Landen; Blake Goodman; Ashwini A Katre; Adam D Steg; Alpa M Nick; Rebecca L Stone; Lance D Miller; Pablo Vivas Mejia; Nicolas B Jennings; David M Gershenson; Robert C Bast; Robert L Coleman; Gabriel Lopez-Berestein; Anil K Sood Journal: Mol Cancer Ther Date: 2010-10-01 Impact factor: 6.261
Authors: Marijke Kamsteeg; Thomas Rutherford; Eva Sapi; Bozena Hanczaruk; Shoreh Shahabi; Maryann Flick; David Brown; Gil Mor Journal: Oncogene Date: 2003-05-01 Impact factor: 9.867
Authors: Emiliano Cocco; Erik M Shapiro; Sara Gasparrini; Salvatore Lopez; Carlton L Schwab; Stefania Bellone; Ileana Bortolomai; Natalia J Sumi; Elena Bonazzoli; Roberta Nicoletti; Yang Deng; W Mark Saltzman; Caroline J Zeiss; Floriana Centritto; Jonathan D Black; Dan-Arin Silasi; Elena Ratner; Masoud Azodi; Thomas J Rutherford; Peter E Schwartz; Sergio Pecorelli; Alessandro D Santin Journal: Int J Cancer Date: 2015-08-18 Impact factor: 7.396
Authors: Jonas Protze; Miriam Eichner; Anna Piontek; Stefan Dinter; Jan Rossa; Kinga Grażyna Blecharz; Peter Vajkoczy; Joerg Piontek; Gerd Krause Journal: Cell Mol Life Sci Date: 2014-10-24 Impact factor: 9.261
Authors: Christopher Breed; Douglas A Hicks; Patricia G Webb; Carly E Galimanis; Benjamin G Bitler; Kian Behbakht; Heidi K Baumgartner Journal: Mol Cancer Res Date: 2019-01-03 Impact factor: 5.852